Golf Legend Bernhard Langer Signs With Skechers
Two-Time Masters Champion Competing in Skechers GOLF Footwear in Return to Augusta
LOS ANGELES, April 09, 2025--(BUSINESS WIRE)--Golf legend and two-time Masters champion Bernhard Langer signs on with Skechers and will wear the brand's golf footwear for his return to Augusta this weekend. The PGA Tour Champions and European Senior Tour pro is set to bring Comfort That Performs® to the course as he competes in the Skechers Blade featuring Skechers Hands Free Slip-ins® technology in a special colorway that celebrates the event.
"I've been playing golf for a long time and Skechers is the first brand I've worked with that really understands comfort on the course," said Bernhard Langer. "Their Skechers Slip-ins technology was perfect to help me through my Achilles rehab over the last year. That easy-on and off hands-free design with all the cushioning has made it so easy to feel confident for my return to Augusta."
"It's a privilege for Skechers to be on the course in Augusta with Bernhard Langer—an icon who has so much history at this tournament," added Michael Greenberg, president of Skechers. "We collaborate with pros on tour to ensure that our footwear has the performance and comfort they need to perform at their best. Bernhard's inspiring comeback at age 67 illustrates how important feeling good is to overcoming adversity—something that any player can experience with Skechers golf shoes."
The Skechers GO GOLF Blade that Bernhard Langer and fellow Skechers athlete Matt Fitzpatrick will wear at The Masters features Skechers Hands Free Slip-ins® technology. This waterproof design features lightweight and resilient ECOFLIGHT™ cushioning made with at least 10% recycled materials, a GRIPFLEX spikeless TPU outsole providing superior traction and stability, plus a high-performance Resamax® sockliner for all-day comfort on the course.
German golfer Bernhard Langer has been competing professionally since 1972 and has earned numerous accolades and more than 120 worldwide victories through a storied career spanning over 50 years. Langer holds the all-time record for most PGA Tour Champions wins at 47—including 12 Champions tour major victories and winning the Charles Schwab Cup six times. His 42 career wins on the European Tour rank 2nd all-time. Langer previously won The Masters twice—in 1985 and 1993—and will return to Augusta this year. He's received various awards throughout his career including winning the Byron Nelson Award for PGA Tour Champions player of the year seven times and earning the prestigious Payne Stewart Award in 2018.
Langer joins a Skechers roster that includes golfers Matt Fitzpatrick and Brooke Henderson. Additional elite athletes around the world competing in Skechers Performance footwear includes basketball stars Julius Randle, Norman Powell, Terance Mann, Joel Embiid, Rickea Jackson and Kiki Iriafen; soccer players Harry Kane, Baris Alper Yilmaz, Isco Alarcón and Mohammed Kudus; pickleball pros Tyson McGuffin and Catherine Parenteau; cricket players Jasprit Bumrah, Ishan Kishan and Yastika Bhatia; and baseball players Clayton Kershaw and Aaron Nola, among others.
Skechers golf footwear is available globally at Skechers retail stores and skechers.com as well as select retail partners, including specialty golf pro shops.
About SKECHERS U.S.A., Inc.
Skechers (NYSE:SKX), The Comfort Technology Company® based in Southern California, designs, develops and markets a diverse range of lifestyle and performance footwear, apparel and accessories for men, women and children. The Company's collections are available in 180 countries and territories through department and specialty stores, and direct to consumers through skechers.com and approximately 5,300 Skechers retail stores. A Fortune 500® company, Skechers manages its international business through a network of wholly-owned subsidiaries, joint venture partners, and distributors. For more information, please visit about.skechers.com and follow us on Facebook, Instagram and TikTok.
This announcement contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include, without limitation, Skechers' future domestic and international growth, financial results and operations including expected net sales and earnings, its development of new products, future demand for its products, its planned domestic and international expansion, opening of new stores and additional expenditures, and advertising and marketing initiatives. Forward-looking statements can be identified by the use of forward-looking language such as "believe," "anticipate," "expect," "estimate," "intend," "plan," "project," "will," "could," "may," "might," or any variations of such words with similar meanings. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements. Factors that might cause or contribute to such differences include the disruption of business and operations due to the COVID-19 pandemic; delays or disruptions in our supply chain; international economic, political and market conditions including the effects of inflation, tariffs and foreign currency exchange rate fluctuations around the world, the challenging consumer retail markets in the United States, and the impact of wars, acts of war and other conflicts around the world; sustaining, managing and forecasting costs and proper inventory levels; losing any significant customers; decreased demand by industry retailers and cancellation of order commitments due to the lack of popularity of particular designs and/or categories of products; maintaining brand image and intense competition among sellers of footwear for consumers, especially in the highly competitive performance footwear market; anticipating, identifying, interpreting or forecasting changes in fashion trends, consumer demand for the products and the various market factors described above; sales levels during the spring, back-to-school and holiday selling seasons; and other factors referenced or incorporated by reference in Skechers' annual report on Form 10-K for the year ended December 31, 2024 and its quarterly reports on Form 10-Q in 2025. Taking these and other risk factors associated with the COVID-19 pandemic into consideration, the dynamic nature of these circumstances means that what is stated in this press release could change at any time, and as a result, actual results could differ materially from those contemplated by such forward-looking statements. The risks included here are not exhaustive. Skechers operates in a very competitive and rapidly changing environment. New risks emerge from time to time and we cannot predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on forward-looking statements as a prediction of actual results. Moreover, reported results should not be considered an indication of future performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409713952/en/
Contacts
Media Contact: Jennifer ClaySKECHERS U.S.A., Inc.jennc@skechers.com
Alexia ParksSkechers USA Ltd.alexia.parks@skechers.com +44 (0) 1707 655 955
Kathrin JägerSkechers USA Deutschlandkathrin.jaeger@eu.skechers.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
44 minutes ago
US Open '25: Oakmont's par-3 8th hole requires removing a head cover
OAKMONT, Pa. -- Maybe no one would complain about the eighth hole at Oakmont Country Club if the term 'par' had never been created in championship golf. But there it sits in the middle of the this tough U.S. course, the longest par 3 in major championship history, 289 yards on the scorecard and certain to top 300 yards in actual distance for one round, just as it did in 2007 at Oakmont. 'I couldn't tell you a par 3 over 250 yards that's good, architecturally,' said Justin Thomas, who took a scouting trip to Oakmont two weeks before it hosts the U.S. Open for a 10th time. 'That's not my favorite hole in the world,' he said. 'I think you could do some other things with that. But everyone's going to have to play the same hole and going to have to execute the same shots, and I would love four 3s on it right now if I could take it.' Jack Nicklaus, who won the first of his 18 professional majors at Oakmont in the 1962 U.S. Open, was asked what he thought about the par-3 eighth. 'I haven't played it since they lengthened it to be a short par 5,' Nicklaus said with a smile. Viktor Hovland speaks for the majority when he said the best par 3s in golf are under 200 yards. But the topic on this day was 300 yards — more or less, depending on how the USGA sets it up each round. Hovland was not a fan. 'As soon as you start to take head covers off on par 3s, I just think it gets a little silly,' he said. This is nothing new in major championship golf. The PGA Championship at Quail Hollow last month featured the 252-yard sixth hole that required a fairway metal for some. The toughest par 3 at the Masters is the 240-yard fourth. And last summer at Royal Troon in the wind and rain, Scottie Scheffler hit his best 3-wood of the year into the par-3 17th on Saturday. There's no doubting No. 8 is a tough hole. A bunker named 'Sahara' juts out some 80 yards before the green. That's easy enough to carry, and then the ball runs onto a putting surfaces that is not as contoured as the others at Oakmont. It's just long. And the numbers indicate it is hard. It ranked No. 8 in difficulty in 2016, with 36% of the field hitting the green in regulation. Go back to 2007 and it ranked No. 4 in difficulty, with 33% of the field finding the green. 'The psychology of par is amazing, which goes to the point of long par 3s,' said Geoff Ogilvy, a U.S. Open champion and now highly regarded in golf course design. 'If it's a par 5 and you're coming in with a fairway metal, you're thinking there's a chance you can make 3,' he said. 'But if it's a par 3, you hope you don't make 4 or 5. And you've got it off a tee! ... No one likes to get a wood out on a par 3. There's a bit of ego involved. But sometimes you have to." Ogilvy presented one other observation about the par-3 eighth at Oakmont that at least should give critics pause. 'Eight at Oakmont almost is the easiest of the four par 3s, even though it's so long," he said. 'It has a wide fairway and probably is the only flat green on the course so you can run it up. I think it's too much at 300 yards. But like at 250, it's a really good hole.' John Bodenhamer, the USGA officer in charge of setting up the course, has said the tee and the pin will be adjusted enough to make it play 301 yards for one round — not 300, but 301. That's part of the fun the USGA likes to have, but not always. The distance for the par-3 11th at Los Angeles Country Club was 299 yards in the 2023 U.S. Open (there is a 40-foot drop in elevation), and the seventh hole at LACC also measured one yard short of a perfect game in bowling. Both of those were in the second round. Phil Mickelson was fuming over the 274-yard third hole in the final round of the 2013 U.S. Open at Merion, where he made double bogey. He was overheard telling an official, 'That's terrible — 274, we can't even reach it.' As for Oakmont, it's worth noting when Johnny Miller had his historic 63 in the final round to win the U.S. Open, his only bogey came at the par-3 eighth. Given the modern game, maybe the value of a super long par 3 is for players to show they can hit a long iron or fairway metal. Ludvig Aberg was asked how often he hits a 3-iron. 'I don't carry one,' the big-hitting Swede said. He has a 4-iron and then swaps out the 3-iron with a 7-wood. But he brings his 3-iron with him in case it makes sense. 'You don't get a lot of long irons into par 4s,' Aberg said. 'It would be a second shot into a par 5. I've never had anything against a long par 3. I guess I'm different.' Harris English played Oakmont in the 2016 U.S. Open and had no beef with No. 8 because 'it gives you room to play.' But when asked for some of the other long par 3s he likes, English struggled to come up with even a short list. 'The long ones aren't as memorable,' he said.
Yahoo
an hour ago
- Yahoo
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. About Phathom Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company's website at and follow on LinkedIn and StatementsThis press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Phathom's commercialization plans. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom's business, including, without limitation: the timing of the correction to the Orange Book; the expected duration of patent term extension for VOQUEZNA; we may not be able to successfully commercialize VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom's ability to obtain and maintain intellectual property protection, including patent term extensions, and non-patent regulatory exclusivity for vonoprazan; Phathom may face competition earlier than expected if it loses or fails to obtain any of its patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets; Phathom's ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for vonoprazan; and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. MEDIA CONTACTNick Benedetto1-877-742-8466media@ INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@ © 2025 Phathom Pharmaceuticals. All rights VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
